SVB Leerink Starts Zentalis Pharmaceuticals (ZNTL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $2.32 -3.33%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
SVB Leerink analyst Andrew Berens initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $31.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Starts Viper Energy (VNOM) at Sector Outperform
- Scotiabank Starts Magnolia Oil & Gas Corp. (MGY) at Sector Outperform
- Scotiabank Starts SM Energy (SM) at Sector Perform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Andrew BerensSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
